CA2 and SLC4A8 |
carbonic anhydrase II |
solute carrier family 4, sodium bicarbonate cotransporter, member 8 |
- O2/CO2 exchange in erythrocytes
- Erythrocytes take up carbon dioxide and release oxygen
- Erythrocytes take up oxygen and release carbon dioxide
- Reversible hydration of carbon dioxide
|
- Transport of inorganic cations/anions and amino acids/oligopeptides
- SLC-mediated transmembrane transport
- Bicarbonate transporters
|
- Methyclothiazide
- Topiramate
- Ethoxzolamide
- Bendroflumethiazide
- Benzthiazide
- Cyclothiazide
- Furosemide
- Methazolamide
- Hydroflumethiazide
- Acetazolamide
- Dorzolamide
- Chlorothiazide
- Zonisamide
- Hydrochlorothiazide
- Trichlormethiazide
- Ethinamate
- Diazoxide
- Dichlorphenamide
- Brinzolamide
- Quinethazone
- 4-(Hydroxymercury)Benzoic Acid
- N-Benzyl-4-Sulfamoyl-Benzamide
- 4-Flourobenzenesulfonamide
- Formic Acid
- AL5424
- N-(2-Flouro-Benzyl)-4-Sulfamoyl-Benzamide
- 3,5-Difluorobenzenesulfonamide
- Al7089a
- 4-(Aminosulfonyl)-N-[(2,4,6-Trifluorophenyl)Methyl]-Benzamide
- 6-Oxo-8,9,10,11-Tetrahydro-7h-Cyclohepta[C][1]Benzopyran-3-O-Sulfamate
- 4-(Aminosulfonyl)-N-[(4-Fluorophenyl)Methyl]-Benzamide
- (R)-N-(3-Indol-1-Yl-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide
- Aminodi(Ethyloxy)Ethylaminocarbonylbenzenesulfonamide
- AL7182
- N-(2,3,4,5,6-Pentaflouro-Benzyl)-4-Sulfamoyl-Benzamide
- Cyanamide
- 4-(Aminosulfonyl)-N-[(3,4,5-Trifluorophenyl)Methyl]-Benzamide
- Dansylamide
- Sulfamic Acid 2,3-O-(1-Methylethylidene)-4,5-O-Sulfonyl-Beta-Fructopyranose Ester
- N-(2-Thienylmethyl)-2,5-Thiophenedisulfonamide
- 4-(Aminosulfonyl)-N-[(2,5-Difluorophenyl)Methyl]-Benzamide
- AL7099A
- Al-6619, [2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide,2-(3-Hydroxyphenyl)-3-(4-Morpholinyl)-, 1,1-Dioxide]
- 2,6-Difluorobenzenesulfonamide
- 1-Methyl-3-Oxo-1,3-Dihydro-Benzo[C]Isothiazole-5-Sulfonic Acid Amide
- (4-sulfamoyl-phenyl)-thiocarbamic acid O-(2-thiophen-3-yl-ethyl) ester
- 4-Methylimidazole
- AL5927
- 1,2,4-Triazole
- N-[2-(1h-Indol-5-Yl)-Butyl]-4-Sulfamoyl-Benzamide
- Al-6629, [2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide,2-(3-Methoxyphenyl)-3-(4-Morpholinyl)-, 1,1-Dioxide]
- Methyl Mercury Ion
- 4-Sulfonamide-[1-(4-Aminobutane)]Benzamide
- N-(2,6-Diflouro-Benzyl)-4-Sulfamoyl-Benzamide
- AL4623
- Urea
- (S)-N-(3-Indol-1-Yl-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide
- Mercuribenzoic Acid
- 4-Sulfonamide-[4-(Thiomethylaminobutane)]Benzamide
- (4s-Trans)-4-(Methylamino)-5,6-Dihydro-6-Methyl-4h-Thieno(2,3-B)Thiopyran-2-Sulfonamide-7,7-Dioxide
- AL5300
- 4-(Aminosulfonyl)-N-[(2,4-Difluorophenyl)Methyl]-Benzamide
- 3-Mercuri-4-Aminobenzenesulfonamide
- AL6528
- 3-Nitro-4-(2-Oxo-Pyrrolidin-1-Yl)-Benzenesulfonamide
- 4-(Aminosulfonyl)-N-[(2,3,4-Trifluorophenyl)Methyl]-Benzamide
- 4-[(3-BROMO-4-O-SULFAMOYLBENZYL)(4-CYANOPHENYL)AMINO]-4H-[1,2,4]-TRIAZOLE
- 4-[(4-O-SULFAMOYLBENZYL)(4-CYANOPHENYL)AMINO]-4H-[1,2,4]-TRIAZOLE
- 1-N-(4-SULFAMOYLPHENYL-ETHYL)-2,4,6-TRIMETHYLPYRIDINIUM
- 5-{[(4-AMINO-3-CHLORO-5-FLUOROPHENYL)SULFONYL]AMINO}-1,3,4-THIADIAZOLE-2-SULFONAMIDE
- 2-(cycloheptylmethyl)-1,1-dioxido-1-benzothiophen-6-yl sulfamate
- N-[(2R)-5-(aminosulfonyl)-2,3-dihydro-1H-inden-2-yl]-2-propylpentanamide
- 5-[(phenylsulfonyl)amino]-1,3,4-thiadiazole-2-sulfonamide
- THIOPHENE-2,5-DISULFONIC ACID 2-AMIDE-5-(4-METHYL-BENZYLAMIDE)
- 4-chloro-N-[(2S)-2-methyl-2,3-dihydro-1H-indol-1-yl]-3-sulfamoylbenzamide
- N-[4-(AMINOSULFONYL)PHENYL]-2-MERCAPTOBENZAMIDE
- (17beta)-17-(cyanomethyl)-2-methoxyestra-1(10),2,4-trien-3-yl sulfamate
- 5-(2-chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide
- PHENYLALANYLAMINODI(ETHYLOXY)ETHYL BENZENESULFONAMIDEAMINOCARBONYLBENZENESULFONAMIDE
- N-(2,3-DIFLUORO-BENZYL)-4-SULFAMOYL-BENZAMIDE
- 2-chloro-5-[(1S)-1-hydroxy-3-oxo-2H-isoindol-1-yl]benzenesulfonamide
- 2-(1,3-thiazol-4-yl)-1H-benzimidazole-5-sulfonamide
- N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDE
- 3-[4-(AMINOSULFONYL)PHENYL]PROPANOIC ACID
- ETHYL 3-[4-(AMINOSULFONYL)PHENYL]PROPANOATE
- indane-5-sulfonamide
- 4-({[(4-METHYLPIPERAZIN-1-YL)AMINO]CARBONOTHIOYL}AMINO)BENZENESULFONAMIDE
- N-({[4-(AMINOSULFONYL)PHENYL]AMINO}CARBONYL)-4-METHYLBENZENESULFONAMIDE
- SULTHIAME
- (9BETA,13ALPHA,14BETA,17ALPHA)-2-METHOXYESTRA-1,3,5(10)-TRIENE-3,17-DIYL DISULFAMATE
- (4aS,4bR,10bS,12aS)-12a-methyl-1,3-dioxo-2-(pyridin-3-ylmethyl)-1,2,3,4,4a,4b,5,6,10b,11,12,12a-dodecahydronaphtho[2,1-f]isoquinolin-8-yl sulfamate
- 6-CHLORO-3-(DICHLOROMETHYL)-3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE-7-SULFONAMIDE 1,1-DIOXIDE
- 2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide
- 6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE
- 4-(2-AMINOETHYL)BENZENESULFONAMIDE
- Ellagic Acid
|
|
|
|
DRD2 and NCS1 |
dopamine receptor D2 |
neuronal calcium sensor 1 |
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- Signaling by GPCR
- GPCR downstream signaling
- Class A/1 (Rhodopsin-like receptors)
- Amine ligand-binding receptors
- G alpha (i) signalling events
- Metabolic disorders of biological oxidation enzymes
- GPCR ligand binding
- Dopamine receptors
|
|
- Ziprasidone
- Cabergoline
- Ropinirole
- Olanzapine
- Clozapine
- Thiethylperazine
- Sulpiride
- Loxapine
- Remoxipride
- Pramipexole
- Promazine
- Prochlorperazine
- Droperidol
- Chlorpromazine
- Buspirone
- Haloperidol
- Triflupromazine
- Amoxapine
- Cinnarizine
- Lisuride
- Fluphenazine
- Thioridazine
- Ergotamine
- Apomorphine
- Trimipramine
- Risperidone
- Propiomazine
- Minaprine
- Trifluoperazine
- Perphenazine
- Flupenthixol
- Amantadine
- Mesoridazine
- Dopamine
- Carphenazine
- Acetophenazine
- Promethazine
- Pimozide
- Doxepin
- Domperidone
- Pergolide
- Bromocriptine
- Ketamine
- Quetiapine
- Metoclopramide
- Levodopa
- Aripiprazole
- Chlorprothixene
- Paliperidone
- Yohimbine
- Methotrimeprazine
- Alizapride
- Rolicyclidine
- Acepromazine
- Molindone
- Pipotiazine
- Thioproperazine
- Thiothixene
- Zuclopenthixol
- Aniracetam
- Fluspirilene
- Tetrabenazine
- Iloperidone
- Rotigotine
- Sertindole
- Asenapine
- Amisulpride
- Lurasidone
|
|
|
|
ESR1 and PIK3R1 |
estrogen receptor 1 |
phosphoinositide-3-kinase, regulatory subunit 1 (alpha) |
- Nuclear signaling by ERBB4
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
- Signaling by ERBB4
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Metabolism of lipids and lipoproteins
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by FGFR1 mutants
- Interleukin-7 signaling
- Role of phospholipids in phagocytosis
- Phospholipid metabolism
- Fcgamma receptor (FCGR) dependent phagocytosis
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- G-protein beta:gamma signalling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- G alpha (q) signalling events
- Signaling by ERBB2
- Signaling by EGFR
- GPCR downstream signaling
- Signaling by Interleukins
- TCR signaling
- Signaling by VEGF
- GP1b-IX-V activation signalling
- Downstream signal transduction
- Signaling by FGFR mutants
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- G alpha (q) signalling events
- Downstream TCR signaling
- Costimulation by the CD28 family
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- Synthesis of PIPs at the plasma membrane
- IRS-related events triggered by IGF1R
- G beta:gamma signalling through PI3Kgamma
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- G alpha (12/13) signalling events
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- PI Metabolism
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- IRS-mediated signalling
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- GPVI-mediated activation cascade
- Interleukin receptor SHC signaling
- Signaling by FGFR1 fusion mutants
- Constitutive Signaling by EGFRvIII
- PI3K Cascade
|
- Diethylstilbestrol
- Chlorotrianisene
- Conjugated Estrogens
- Etonogestrel
- Desogestrel
- Levonorgestrel
- Progesterone
- Raloxifene
- Toremifene
- Medroxyprogesterone
- Estrone
- Tamoxifen
- Estradiol
- Ethynodiol Diacetate
- Clomifene
- Dienestrol
- Fulvestrant
- Norgestimate
- Ethinyl Estradiol
- Melatonin
- Trilostane
- Naloxone
- Fluoxymesterone
- Estramustine
- Mestranol
- Danazol
- Allylestrenol
- Genistein
- Compound 19
- Compound 18
- Compound 4-D
- 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
- 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
- Estriol
- Estropipate
- Quinestrol
- Ospemifene
- 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
- 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol
- [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
- (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
- (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
- 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
- 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
- DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
- 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE
- 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
- RALOXIFENE CORE
|
- Isoproterenol
- (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
|
|
|
PTPN1 and RRAS2 |
protein tyrosine phosphatase, non-receptor type 1 |
related RAS viral (r-ras) oncogene homolog 2 |
- Interferon gamma signaling
- Regulation of IFNA signaling
- Interferon Signaling
- Integrin alphaIIb beta3 signaling
- Cytokine Signaling in Immune system
- Interferon alpha/beta signaling
- Platelet activation, signaling and aggregation
- Platelet Aggregation (Plug Formation)
- Regulation of IFNG signaling
- Growth hormone receptor signaling
|
|
- Tiludronate
- 3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid
- Double Oxidized Cysteine
- Compound 12, N-Acetyl-4-[(Carboxycarbonyl)(2-Carboxyphenyl)Amino]-N-Pentyl-1-Napthylalaniamide
- Compound 9
- 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid
- 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide
- [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid,
- 2-{4-[(2s)-2-[({[(1s)-1-Carboxy-2-Phenylethyl]Amino}Carbonyl)Amino]-3-Oxo-3-(Pentylamino)Propyl]Phenoxy}Malonic Acid
- Compound 19
- Sp7343-Sp7964
- 2-(Oxalyl-Amino)-Benzoic Acid
- {[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid)
- Novo Nordisk a/S Compound
- N-[4-(2-{2-[3-(2-Bromo-Acetylamino)-Propionylamino]-3-Hydroxy-Propionylamino}-Ethyl)-Phenyl]-Oxalamic Acid
- 7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid
- PNU177836
- 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid
- {[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid
- 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide
- 4-Benzoylamino-4-{1-{1-Carbamoyl-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethylcarbamoyl}-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethylcarbamoyl}-Butyric Acid
- N-{1-[5-(1-Carbamoyl-2-Mercapto-Ethylcarbamoyl)-Pentylcarbamoyl]-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethyl}-3-{2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Acetylamino}-Succinamic Acid
- Cysteinesulfonic Acid
- 2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid
- 4-Carbamoyl-4-{[6-(Difluoro-Phosphono-Methyl)-Naphthalene-2-Carbonyl]-Amino}-Butyric Acid
- Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid
- 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid
- N-(Allyloxycarbonyl)-4-[N-(Carboxy-Formyl)-2-(Benzoic Acid)-Amino]-L-Phenylalaninyl-Amino-Butyloxy-(6-Hydroxy-Benzoic Acid Methyl Ester)
- 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide
- [(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid
- {4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid
- 2-(Carboxymethoxy)-5-[(2s)-2-({(2s)-2-[(3-Carboxypropanoyl)Amino] -3-Phenylpropanoyl}Amino)-3-Oxo-3-(Pentylamino)Propyl]Benzoic Acid
- 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID
- 4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID
- 3(S)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID TERT-BUTYL ESTER
- 4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID
- 5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE
- 4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID
- [{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid
- 5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID
- 2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID
- 3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID
- 4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN
- N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE
- 3(R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID TERT-BUTYL ESTER
- 5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE
- 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID
- ISOTHIAZOLIDINONE ANALOG
- 4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid
- PARA-(BENZOYL)-PHENYLALANINE
- 6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID
- (3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER
- 5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE
- 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE
- (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid
|
|
|
|
ACHE and APP |
acetylcholinesterase (Yt blood group) |
amyloid beta (A4) precursor protein |
- Synthesis of PC
- Peptide hormone metabolism
- Synthesis, secretion, and deacylation of Ghrelin
- Metabolism of lipids and lipoproteins
- Neurotransmitter Clearance In The Synaptic Cleft
- Phospholipid metabolism
- Glycerophospholipid biosynthesis
- Transmission across Chemical Synapses
|
- Signaling by GPCR
- Platelet degranulation
- Metabolic disorders of biological oxidation enzymes
- RIP-mediated NFkB activation via ZBP1
- Formyl peptide receptors bind formyl peptides and many other ligands
- Amyloids
- Toll Like Receptor TLR1:TLR2 Cascade
- Peptide ligand-binding receptors
- Toll Like Receptor 5 (TLR5) Cascade
- The NLRP3 inflammasome
- Gastrin-CREB signalling pathway via PKC and MAPK
- Response to elevated platelet cytosolic Ca2+
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- G alpha (i) signalling events
- TRIF-mediated TLR3/TLR4 signaling
- Toll Like Receptor 2 (TLR2) Cascade
- G alpha (q) signalling events
- GPCR downstream signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Platelet activation, signaling and aggregation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- G alpha (q) signalling events
- Class A/1 (Rhodopsin-like receptors)
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- ZBP1(DAI) mediated induction of type I IFNs
- ECM proteoglycans
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Advanced glycosylation endproduct receptor signaling
- Innate Immune System
- Inflammasomes
- Cytosolic sensors of pathogen-associated DNA
- MyD88-independent cascade
- GPCR ligand binding
- Toll-Like Receptors Cascades
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Toll Like Receptor 10 (TLR10) Cascade
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- TRAF6 mediated NF-kB activation
|
- Choline
- Tacrine
- Gallamine Triethiodide
- Pyridostigmine
- Galantamine
- Isoflurophate
- Pralidoxime
- Minaprine
- Donepezil
- Demecarium
- Physostigmine
- Rivastigmine
- Edrophonium
- Ambenonium
- Tubocurarine
- Decamethonium
- Ephedrine
- Neostigmine
- Monoisopropylphosphorylserine
- Huperaine A
- Propidium
- 3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-4-Yl]Hexyl]-Phenanthridinium
- 3,6,9,12,15-Pentaoxaheptadecane
- 1-Deoxy-1-Thio-Heptaethylene Glycol
- (4ar,6s,8ar)-11-[8-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Octyl]-6-Hydroxy-3-Methoxy-5,6,9,10-Tetrahydro-4ah-[1]Benzofuro[3a,3,2-Ef][2]Benzazepin-11-Ium
- Methylphosphonic Acid Ester Group
- Methylphosphinic Acid
- 3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-5-Yl]Hexyl]-Phenanthridinium
- Acetylcholine
- beta-L-fucose
- M-(N,N,N-Trimethylammonio)-2,2,2-Trifluoro-1,1-Dihydroxyethylbenzene
- 2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose
- 2-(N-Morpholino)-Ethanesulfonic Acid
- MF268
- 3-Chloro-9-Ethyl-6,7,8,9,10,11-Hexahydro-7,11-Methanocycloocta[B]Quinolin-12-Amine
- 3-[(1s)-1-(Dimethylamino)Ethyl]Phenol
- (R)-tacrine(10)-hupyridone
- (S)-tacrine(10)-hupyridone
- TACRINE(8)-4-AMINOQUINOLINE
- (9S)-9-[(8-AMMONIOOCTYL)AMINO]-1,2,3,4,9,10-HEXAHYDROACRIDINIUM
- 1-(2-nitrophenyl)-2,2,2-trifluoroethyl]-arsenocholine
- 1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANON-2-YL)METHYL]PIPERIDINE
- 1-[3-({[(4-AMINO-5-FLUORO-2-METHYLQUINOLIN-3-YL)METHYL]THIO}METHYL)PHENYL]-2,2,2-TRIFLUOROETHANE-1,1-DIOL
- (1R)-1,2,2-TRIMETHYLPROPYL (S)-METHYLPHOSPHINATE
- 1S,3AS,8AS-TRIMETHYL-1-OXIDO-1,2,3,3A,8,8A-HEXAHYDROPYRROLO[2,3-B]INDOL-5-YL 2-ETHYLPHENYLCARBAMATE
- 3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-IUM
- 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE
- 2-[4-(DIMETHYLAMINO)PHENYL]-6-HYDROXY-3-METHYL-1,3-BENZOTHIAZOL-3-IUM
|
|
|
|
HSP90AA1 and TOMM40 |
heat shock protein 90kDa alpha (cytosolic), class A member 1 |
translocase of outer mitochondrial membrane 40 homolog (yeast) |
- HSF1 activation
- Regulatory RNA pathways
- Signaling by EGFRvIII in Cancer
- Regulation of PLK1 Activity at G2/M Transition
- Influenza Life Cycle
- Influenza Viral RNA Transcription and Replication
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Uptake and actions of bacterial toxins
- EPH-Ephrin signaling
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- Fcgamma receptor (FCGR) dependent phagocytosis
- Recruitment of mitotic centrosome proteins and complexes
- Regulation of actin dynamics for phagocytic cup formation
- vRNP Assembly
- Influenza Infection
- Signaling by ERBB2
- Signaling by VEGF
- Signaling by EGFR in Cancer
- Sema3A PAK dependent Axon repulsion
- Mitotic G2-G2/M phases
- Uptake and function of diphtheria toxin
- PIWI-interacting RNA (piRNA) biogenesis
- Organelle biogenesis and maintenance
- Axon guidance
- Attenuation phase
- G2/M Transition
- VEGFA-VEGFR2 Pathway
- HSF1-dependent transactivation
- EPHA-mediated growth cone collapse
- Metabolism of nitric oxide
- VEGFR2 mediated vascular permeability
- Loss of Nlp from mitotic centrosomes
- Scavenging by Class F Receptors
- eNOS activation and regulation
- Innate Immune System
- Semaphorin interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Assembly of the primary cilium
- Cellular response to heat stress
- Anchoring of the basal body to the plasma membrane
- Cell Cycle, Mitotic
- eNOS activation
- Loss of proteins required for interphase microtubule organization from the centrosome
- Centrosome maturation
- Constitutive Signaling by EGFRvIII
|
- Mitochondrial protein import
|
- Rifabutin
- Nedocromil
- 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
- Geldanamycin
- 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
- 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
- 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
- 17-Dmag
- 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
- 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
- Adenosine-5\'-Diphosphate
- 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
- 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
- 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
- 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
- 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
- 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
- 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
- N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
- N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
- 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
- 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
- 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
- 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
- (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
- 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
- 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
- N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
- 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
- 4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL
- 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
- 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
- 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
- (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
- 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
- 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
- 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
- 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
- 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
- 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
- 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
- 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
|
|
|
|
SRC and PIK3R1 |
SRC proto-oncogene, non-receptor tyrosine kinase |
phosphoinositide-3-kinase, regulatory subunit 1 (alpha) |
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Metabolism of lipids and lipoproteins
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by FGFR1 mutants
- Interleukin-7 signaling
- Role of phospholipids in phagocytosis
- Phospholipid metabolism
- Fcgamma receptor (FCGR) dependent phagocytosis
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- G-protein beta:gamma signalling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- G alpha (q) signalling events
- Signaling by ERBB2
- Signaling by EGFR
- GPCR downstream signaling
- Signaling by Interleukins
- TCR signaling
- Signaling by VEGF
- GP1b-IX-V activation signalling
- Downstream signal transduction
- Signaling by FGFR mutants
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- G alpha (q) signalling events
- Downstream TCR signaling
- Costimulation by the CD28 family
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- Synthesis of PIPs at the plasma membrane
- IRS-related events triggered by IGF1R
- G beta:gamma signalling through PI3Kgamma
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- G alpha (12/13) signalling events
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- PI Metabolism
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- IRS-mediated signalling
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- GPVI-mediated activation cascade
- Interleukin receptor SHC signaling
- Signaling by FGFR1 fusion mutants
- Constitutive Signaling by EGFRvIII
- PI3K Cascade
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5\'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- RU82129
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric Acid
- RU81843
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
|
- Isoproterenol
- (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
|
|
|
SRC and CD33 |
SRC proto-oncogene, non-receptor tyrosine kinase |
CD33 molecule |
|
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5\'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- RU82129
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric Acid
- RU81843
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
|
|
|
|
SRC and EFNA5 |
SRC proto-oncogene, non-receptor tyrosine kinase |
ephrin-A5 |
|
- EPHA-mediated growth cone collapse
- EPH-ephrin mediated repulsion of cells
- Axon guidance
- EPH-Ephrin signaling
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5\'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- RU82129
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric Acid
- RU81843
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
|
|
|
|
SRC and CD2AP |
SRC proto-oncogene, non-receptor tyrosine kinase |
CD2-associated protein |
|
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5\'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- RU82129
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric Acid
- RU81843
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
|
|
|
|
SRC and GAB2 |
SRC proto-oncogene, non-receptor tyrosine kinase |
GRB2-associated binding protein 2 |
|
- Signaling by GPCR
- Signaling by FGFR in disease
- G-protein beta:gamma signalling
- Cytokine Signaling in Immune system
- Role of LAT2/NTAL/LAB on calcium mobilization
- Signaling by SCF-KIT
- Signaling by Interleukins
- GPCR downstream signaling
- Interleukin receptor SHC signaling
- G beta:gamma signalling through PI3Kgamma
- Signaling by FGFR1 mutants
- Interleukin receptor SHC signaling
- Fc epsilon receptor (FCERI) signaling
- Signaling by FGFR mutants
- GPVI-mediated activation cascade
- Interleukin-2 signaling
- Signaling by FGFR1 fusion mutants
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Innate Immune System
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5\'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- RU82129
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric Acid
- RU81843
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
|
|
|
|
SRC and MPZL1 |
SRC proto-oncogene, non-receptor tyrosine kinase |
myelin protein zero-like 1 |
|
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5\'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- RU82129
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric Acid
- RU81843
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
|
|
|
|
NOS3 and APOE |
nitric oxide synthase 3 (endothelial cell) |
apolipoprotein E |
- Phagosomal maturation (early endosomal stage)
- VEGFA-VEGFR2 Pathway
- eNOS activation
- Metabolism of nitric oxide
- Platelet homeostasis
- Signaling by VEGF
- VEGFR2 mediated vascular permeability
- NOSTRIN mediated eNOS trafficking
- NOSIP mediated eNOS trafficking
- Latent infection of Homo sapiens with Mycobacterium tuberculosis
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- Nitric oxide stimulates guanylate cyclase
- eNOS activation and regulation
|
- Lipoprotein metabolism
- Metabolism of lipids and lipoproteins
- Chylomicron-mediated lipid transport
- Lipid digestion, mobilization, and transport
- Diseases associated with visual transduction
- HDL-mediated lipid transport
- Visual phototransduction
- Scavenging by Class A Receptors
- Retinoid metabolism and transport
|
- L-Arginine
- L-Citrulline
- Tetrahydrobiopterin
- Miconazole
- N,N-dimethylarginine
- L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric Amide
- L-2-Amino-4-(Guanidinooxy)Butyric Acid
- 3-Bromo-7-Nitroindazole
- N-{(4s)-4-Amino-5-[(2-Aminoethyl)Amino]Pentyl}-N\'-Nitroguanidine
- N-(3-(Aminomethyl)Benzyl)Acetamidine
- 1,2,4-Triazole-Carboxamidine
- L-N(Omega)-Nitroarginine-(4r)-Amino-L-Proline Amide
- S,S\'-(1,4-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea
- 7-Nitroindazole
- Ethylisothiourea
- 2-Aminothiazoline
- Se-Ethyl-Isoselenourea
- (6r,1\'r,2\'s)-5,6,7,8 Tetrahydrobiopterin
- 2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine
- N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane
- Hydroxydimethylarsine Oxide
- Heme
- 7-Nitroindazole-2-Carboxamidine
- 6-Nitroindazole
- N-Omega-Hydroxy-L-Arginine
- N5-Iminoethyl-L-Ornithine
- 5,6-Cyclic-Tetrahydropteridine
- S-Ethyl-N-Phenyl-Isothiourea
- S,S\'-(1,3-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea
- 6s-5,6,7,8-Tetrahydrobiopterin
- S-(Dimethylarsenic)Cysteine
- L-Homoarginine
- S-Isopropyl-Isothiourea
- Nitroarginine
- 5-Nitroindazole
- N-(Chlorophenyl)-N\'-Hydroxyguanidine
- (3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine
- 5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE
- ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE
- N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N\'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE
- N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N\'-(3-chlorobenzyl)ethane-1,2-diamine
|
- Human Serum Albumin
- Serum albumin iodonated
|
|
|
NOS3 and APP |
nitric oxide synthase 3 (endothelial cell) |
amyloid beta (A4) precursor protein |
- Phagosomal maturation (early endosomal stage)
- VEGFA-VEGFR2 Pathway
- eNOS activation
- Metabolism of nitric oxide
- Platelet homeostasis
- Signaling by VEGF
- VEGFR2 mediated vascular permeability
- NOSTRIN mediated eNOS trafficking
- NOSIP mediated eNOS trafficking
- Latent infection of Homo sapiens with Mycobacterium tuberculosis
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- Nitric oxide stimulates guanylate cyclase
- eNOS activation and regulation
|
- Signaling by GPCR
- Platelet degranulation
- Metabolic disorders of biological oxidation enzymes
- RIP-mediated NFkB activation via ZBP1
- Formyl peptide receptors bind formyl peptides and many other ligands
- Amyloids
- Toll Like Receptor TLR1:TLR2 Cascade
- Peptide ligand-binding receptors
- Toll Like Receptor 5 (TLR5) Cascade
- The NLRP3 inflammasome
- Gastrin-CREB signalling pathway via PKC and MAPK
- Response to elevated platelet cytosolic Ca2+
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- G alpha (i) signalling events
- TRIF-mediated TLR3/TLR4 signaling
- Toll Like Receptor 2 (TLR2) Cascade
- G alpha (q) signalling events
- GPCR downstream signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Platelet activation, signaling and aggregation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- G alpha (q) signalling events
- Class A/1 (Rhodopsin-like receptors)
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- ZBP1(DAI) mediated induction of type I IFNs
- ECM proteoglycans
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Advanced glycosylation endproduct receptor signaling
- Innate Immune System
- Inflammasomes
- Cytosolic sensors of pathogen-associated DNA
- MyD88-independent cascade
- GPCR ligand binding
- Toll-Like Receptors Cascades
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Toll Like Receptor 10 (TLR10) Cascade
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- TRAF6 mediated NF-kB activation
|
- L-Arginine
- L-Citrulline
- Tetrahydrobiopterin
- Miconazole
- N,N-dimethylarginine
- L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric Amide
- L-2-Amino-4-(Guanidinooxy)Butyric Acid
- 3-Bromo-7-Nitroindazole
- N-{(4s)-4-Amino-5-[(2-Aminoethyl)Amino]Pentyl}-N\'-Nitroguanidine
- N-(3-(Aminomethyl)Benzyl)Acetamidine
- 1,2,4-Triazole-Carboxamidine
- L-N(Omega)-Nitroarginine-(4r)-Amino-L-Proline Amide
- S,S\'-(1,4-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea
- 7-Nitroindazole
- Ethylisothiourea
- 2-Aminothiazoline
- Se-Ethyl-Isoselenourea
- (6r,1\'r,2\'s)-5,6,7,8 Tetrahydrobiopterin
- 2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine
- N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane
- Hydroxydimethylarsine Oxide
- Heme
- 7-Nitroindazole-2-Carboxamidine
- 6-Nitroindazole
- N-Omega-Hydroxy-L-Arginine
- N5-Iminoethyl-L-Ornithine
- 5,6-Cyclic-Tetrahydropteridine
- S-Ethyl-N-Phenyl-Isothiourea
- S,S\'-(1,3-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea
- 6s-5,6,7,8-Tetrahydrobiopterin
- S-(Dimethylarsenic)Cysteine
- L-Homoarginine
- S-Isopropyl-Isothiourea
- Nitroarginine
- 5-Nitroindazole
- N-(Chlorophenyl)-N\'-Hydroxyguanidine
- (3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine
- 5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE
- ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE
- N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N\'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE
- N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N\'-(3-chlorobenzyl)ethane-1,2-diamine
|
|
|
|
NOS3 and PSEN1 |
nitric oxide synthase 3 (endothelial cell) |
presenilin 1 |
- Phagosomal maturation (early endosomal stage)
- VEGFA-VEGFR2 Pathway
- eNOS activation
- Metabolism of nitric oxide
- Platelet homeostasis
- Signaling by VEGF
- VEGFR2 mediated vascular permeability
- NOSTRIN mediated eNOS trafficking
- NOSIP mediated eNOS trafficking
- Latent infection of Homo sapiens with Mycobacterium tuberculosis
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- Nitric oxide stimulates guanylate cyclase
- eNOS activation and regulation
|
- Degradation of the extracellular matrix
|
- L-Arginine
- L-Citrulline
- Tetrahydrobiopterin
- Miconazole
- N,N-dimethylarginine
- L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric Amide
- L-2-Amino-4-(Guanidinooxy)Butyric Acid
- 3-Bromo-7-Nitroindazole
- N-{(4s)-4-Amino-5-[(2-Aminoethyl)Amino]Pentyl}-N\'-Nitroguanidine
- N-(3-(Aminomethyl)Benzyl)Acetamidine
- 1,2,4-Triazole-Carboxamidine
- L-N(Omega)-Nitroarginine-(4r)-Amino-L-Proline Amide
- S,S\'-(1,4-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea
- 7-Nitroindazole
- Ethylisothiourea
- 2-Aminothiazoline
- Se-Ethyl-Isoselenourea
- (6r,1\'r,2\'s)-5,6,7,8 Tetrahydrobiopterin
- 2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine
- N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane
- Hydroxydimethylarsine Oxide
- Heme
- 7-Nitroindazole-2-Carboxamidine
- 6-Nitroindazole
- N-Omega-Hydroxy-L-Arginine
- N5-Iminoethyl-L-Ornithine
- 5,6-Cyclic-Tetrahydropteridine
- S-Ethyl-N-Phenyl-Isothiourea
- S,S\'-(1,3-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea
- 6s-5,6,7,8-Tetrahydrobiopterin
- S-(Dimethylarsenic)Cysteine
- L-Homoarginine
- S-Isopropyl-Isothiourea
- Nitroarginine
- 5-Nitroindazole
- N-(Chlorophenyl)-N\'-Hydroxyguanidine
- (3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine
- 5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE
- ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE
- N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N\'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE
- N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N\'-(3-chlorobenzyl)ethane-1,2-diamine
|
|
|
|
NOS3 and PSEN2 |
nitric oxide synthase 3 (endothelial cell) |
presenilin 2 |
- Phagosomal maturation (early endosomal stage)
- VEGFA-VEGFR2 Pathway
- eNOS activation
- Metabolism of nitric oxide
- Platelet homeostasis
- Signaling by VEGF
- VEGFR2 mediated vascular permeability
- NOSTRIN mediated eNOS trafficking
- NOSIP mediated eNOS trafficking
- Latent infection of Homo sapiens with Mycobacterium tuberculosis
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- Nitric oxide stimulates guanylate cyclase
- eNOS activation and regulation
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Axon guidance
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Signaling by NOTCH2
- EPH-ephrin mediated repulsion of cells
- Signaling by NOTCH1
- EPH-Ephrin signaling
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
- Signaling by NOTCH4
- Regulated proteolysis of p75NTR
- Signalling by NGF
- Cell death signalling via NRAGE, NRIF and NADE
- Signaling by NOTCH
- p75 NTR receptor-mediated signalling
- Signaling by ERBB4
- NOTCH2 Activation and Transmission of Signal to the Nucleus
- Activated NOTCH1 Transmits Signal to the Nucleus
- Nuclear signaling by ERBB4
- NRIF signals cell death from the nucleus
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by NOTCH3
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
|
- L-Arginine
- L-Citrulline
- Tetrahydrobiopterin
- Miconazole
- N,N-dimethylarginine
- L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric Amide
- L-2-Amino-4-(Guanidinooxy)Butyric Acid
- 3-Bromo-7-Nitroindazole
- N-{(4s)-4-Amino-5-[(2-Aminoethyl)Amino]Pentyl}-N\'-Nitroguanidine
- N-(3-(Aminomethyl)Benzyl)Acetamidine
- 1,2,4-Triazole-Carboxamidine
- L-N(Omega)-Nitroarginine-(4r)-Amino-L-Proline Amide
- S,S\'-(1,4-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea
- 7-Nitroindazole
- Ethylisothiourea
- 2-Aminothiazoline
- Se-Ethyl-Isoselenourea
- (6r,1\'r,2\'s)-5,6,7,8 Tetrahydrobiopterin
- 2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine
- N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane
- Hydroxydimethylarsine Oxide
- Heme
- 7-Nitroindazole-2-Carboxamidine
- 6-Nitroindazole
- N-Omega-Hydroxy-L-Arginine
- N5-Iminoethyl-L-Ornithine
- 5,6-Cyclic-Tetrahydropteridine
- S-Ethyl-N-Phenyl-Isothiourea
- S,S\'-(1,3-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea
- 6s-5,6,7,8-Tetrahydrobiopterin
- S-(Dimethylarsenic)Cysteine
- L-Homoarginine
- S-Isopropyl-Isothiourea
- Nitroarginine
- 5-Nitroindazole
- N-(Chlorophenyl)-N\'-Hydroxyguanidine
- (3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine
- 5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE
- ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE
- N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N\'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE
- N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N\'-(3-chlorobenzyl)ethane-1,2-diamine
|
|
|
|
PPARG and APP |
peroxisome proliferator-activated receptor gamma |
amyloid beta (A4) precursor protein |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- Signaling by GPCR
- Platelet degranulation
- Metabolic disorders of biological oxidation enzymes
- RIP-mediated NFkB activation via ZBP1
- Formyl peptide receptors bind formyl peptides and many other ligands
- Amyloids
- Toll Like Receptor TLR1:TLR2 Cascade
- Peptide ligand-binding receptors
- Toll Like Receptor 5 (TLR5) Cascade
- The NLRP3 inflammasome
- Gastrin-CREB signalling pathway via PKC and MAPK
- Response to elevated platelet cytosolic Ca2+
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- G alpha (i) signalling events
- TRIF-mediated TLR3/TLR4 signaling
- Toll Like Receptor 2 (TLR2) Cascade
- G alpha (q) signalling events
- GPCR downstream signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Platelet activation, signaling and aggregation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- G alpha (q) signalling events
- Class A/1 (Rhodopsin-like receptors)
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- ZBP1(DAI) mediated induction of type I IFNs
- ECM proteoglycans
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Advanced glycosylation endproduct receptor signaling
- Innate Immune System
- Inflammasomes
- Cytosolic sensors of pathogen-associated DNA
- MyD88-independent cascade
- GPCR ligand binding
- Toll-Like Receptors Cascades
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Toll Like Receptor 10 (TLR10) Cascade
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- TRAF6 mediated NF-kB activation
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
GABRA4 and APP |
gamma-aminobutyric acid (GABA) A receptor, alpha 4 |
amyloid beta (A4) precursor protein |
- GABA receptor activation
- Ion channel transport
- GABA A receptor activation
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Ligand-gated ion channel transport
- Orphan transporters
- Transmission across Chemical Synapses
|
- Signaling by GPCR
- Platelet degranulation
- Metabolic disorders of biological oxidation enzymes
- RIP-mediated NFkB activation via ZBP1
- Formyl peptide receptors bind formyl peptides and many other ligands
- Amyloids
- Toll Like Receptor TLR1:TLR2 Cascade
- Peptide ligand-binding receptors
- Toll Like Receptor 5 (TLR5) Cascade
- The NLRP3 inflammasome
- Gastrin-CREB signalling pathway via PKC and MAPK
- Response to elevated platelet cytosolic Ca2+
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- G alpha (i) signalling events
- TRIF-mediated TLR3/TLR4 signaling
- Toll Like Receptor 2 (TLR2) Cascade
- G alpha (q) signalling events
- GPCR downstream signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Platelet activation, signaling and aggregation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- G alpha (q) signalling events
- Class A/1 (Rhodopsin-like receptors)
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- ZBP1(DAI) mediated induction of type I IFNs
- ECM proteoglycans
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Advanced glycosylation endproduct receptor signaling
- Innate Immune System
- Inflammasomes
- Cytosolic sensors of pathogen-associated DNA
- MyD88-independent cascade
- GPCR ligand binding
- Toll-Like Receptors Cascades
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Toll Like Receptor 10 (TLR10) Cascade
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- TRAF6 mediated NF-kB activation
|
- Lorazepam
- Ethchlorvynol
- Temazepam
- Butabarbital
- Butalbital
- Talbutal
- Pentobarbital
- Clobazam
- Meprobamate
- Alprazolam
- Secobarbital
- Metharbital
- Chlordiazepoxide
- Thiopental
- Clorazepate
- Midazolam
- Flurazepam
- Primidone
- Oxazepam
- Methylphenobarbital
- Triazolam
- Clonazepam
- Phenobarbital
- Amobarbital
- Aprobarbital
- Butethal
- Heptabarbital
- Hexobarbital
- Barbital
- Barbituric acid derivative
- Flunitrazepam
- Bromazepam
- Nitrazepam
|
|
|
|
BCHE and COLQ |
butyrylcholinesterase |
collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase |
- Synthesis of PC
- Peptide hormone metabolism
- Synthesis, secretion, and deacylation of Ghrelin
- Metabolism of lipids and lipoproteins
- Neurotransmitter Clearance In The Synaptic Cleft
- Phospholipid metabolism
- Glycerophospholipid biosynthesis
- Transmission across Chemical Synapses
|
|
- Choline
- Tacrine
- Dipivefrin
- Pyridostigmine
- Galantamine
- Isoflurophate
- Pralidoxime
- Malathion
- Hexafluronium
- Demecarium
- Rivastigmine
- Edrophonium
- Echothiophate
- Mivacurium
- Beta-D-Mannose
- Diethylphosphono Group
- Methylphosphinic Acid
- Alpha-D-Mannose
- Butanoic Acid
- 9-N-Phenylmethylamino-Tacrine
- 2-(N-Morpholino)-Ethanesulfonic Acid
- Ethyl Dihydrogen Phosphate
- Butyrylthiocholine
- Monoisopropyl Ester Phosphonic Acid Group
- DODECANESULFONATE ION
- 9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE
- (1R)-MENTHYL HEXYL PHOSPHONATE GROUP
- (1S)-MENTHYL HEXYL PHOSPHONATE GROUP
- ETHYL HYDROGEN DIETHYLAMIDOPHOSPHATE
|
|
|
|
DRD3 and NCS1 |
dopamine receptor D3 |
neuronal calcium sensor 1 |
|
|
- Ziprasidone
- Cabergoline
- Ropinirole
- Olanzapine
- Clozapine
- Sulpiride
- Remoxipride
- Pramipexole
- Haloperidol
- Lisuride
- Apomorphine
- Risperidone
- Dopamine
- Pimozide
- Domperidone
- Pergolide
- Bromocriptine
- Quetiapine
- Levodopa
- Aripiprazole
- Chlorprothixene
- Paliperidone
- Yohimbine
- Methotrimeprazine
- Iloperidone
- Rotigotine
- Asenapine
- Amisulpride
|
|
|
|